Key result
CXCR7 antibody attenuates mineralocorticoid-induced cardiac and renal fibrosis in mice without affecting blood pressure.
Why the study?
Cardiorenal fibrosis is common in chronic cardiovascular disease and chemokines may drive fibrosis, leading to the hypothesis that the conserved chemokine receptor CXCR7 contributes to cardiac and renal fibrosis.
Does CXCR7 antagonism reduce cardiac and renal fibrosis in a mouse model of mineralocorticoid excess?
Does CXCR7 antagonism reduce cardiac and renal fibrosis in a mouse model of mineralocorticoid excess?
Antagonism of the chemokine receptor CXCR7 attenuates cardiac and renal fibrosis in a mineralocorticoid excess mouse model, suggesting a potential therapeutic target for cardiorenal fibrosis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for CXCR7 antagonism in cardiorenal fibrosis; does not yet inform clinical practice.
Cardiorenal fibrosis is a common feature of chronic cardiovascular disease and recent data suggests that cytokines and chemokines may also drive fibrosis. Here we tested the hypothesis that CXCR7, a highly conserved chemokine receptor, contributes to cardiac and renal fibrosis. We generated an anti-mouse CXCR7-specific monoclonal antibody (CXCR7 mAb) and tested its anti-fibrotic actions in cardiorenal fibrosis induced using the deoxycorticosterone acetate/uni-nephrectomy (DOCA-UNX) model. CXCR7 mAb treatment (10 mg/kg, twice weekly for 6 weeks) significantly attenuated the development of cardiac and renal fibrosis, and reduced fibrotic and inflammatory gene expression levels, in the absence of an effect on blood pressure. Immunohistochemical analysis demonstrated an increase in the vascular expression of CXCR7 in DOCA-UNX-treated mice. This study demonstrated that a CXCR7 mediated pathway plays a significant role in cardiac and renal fibrosis induced by DOCA-UNX treatment. Accordingly, antagonism of CXCR7 may provide a therapeutic opportunity to mitigate against fibrosis in the setting of mineralocorticoid excess.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied Cardiorenal fibrosis (n=27). anti-CXCR7 monoclonal antibody (clone 10D1) vs. Isotype control or saline was evaluated on Cardiac and renal fibrosis (collagen deposition) (p=<0.001). CXCR7 monoclonal antibody treatment significantly attenuated the development of cardiac and renal fibrosis induced by mineralocorticoid excess in mice, without affecting blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: